
USD $6204.60
Retevmo (Selpercatinib) is a targeted therapy designed for the treatment of specific types of cancer. The active ingredient, Selpercatinib, is a potent selective inhibitor of RET (rearranged during transfection) tyrosine kinase, which plays a crucial role in the growth and proliferation of cancer cells. This medication is primarily indicated for patients with RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid cancer (MTC).